This Down-on-Its-Luck Biotech Could Surge 150%, Wall Street Says. Should You Buy the Stock?
(NASDAQ: NVAX) shares have brought investors extremely good times and extremely bad times. They soared back in 2020 on hopes the biotech would score a win with its coronavirus vaccine candidate. But as Novavax fell behind in the race, the stock retreated.
Since then, Novavax has launched a vaccine, but the late-to-market entry meant it missed out on the biggest revenue opportunity. After all, vaccine demand is on the decline as we head toward a post-pandemic situation.
But that isn't holding back Wall Street's optimism about Novavax's stock performance potential. The average analyst forecast calls for a 150% increase over the coming 12 months.
Source Fool.com
Novavax Inc. Aktie
10,54 €
1,39 %
Leichtes Buy-Überwiegen bei Novavax Inc. im Vergleich zu Sell-Einschätzungen.
Das von der Community festgelegte Kursziel für Novavax Inc. von 22 € würde den aktuellen Kurs von 10.54 € mehr als verdoppeln.
